skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 16,484  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Refined by: language: Japanese remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Material Type:
Article
Add to My Research

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine, 2021-05, Vol.384 (20), p.1885-1898 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2102214 ;PMID: 33725432

Digital Resources/Online E-Resources

2
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Material Type:
Article
Add to My Research

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

BMJ (Online), 2021-05, Vol.373, p.n1088-n1088 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. BMJ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.n1088 ;PMID: 33985964

Full text available

3
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Material Type:
Article
Add to My Research

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Nature (London), 2021-05, Vol.593 (7857), p.130-135 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03398-2 ;PMID: 33684923

Full text available

4
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Material Type:
Article
Add to My Research

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Nature reviews. Immunology, 2022-01, Vol.22 (1), p.57-65 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;COPYRIGHT 2022 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-021-00662-4 ;PMID: 34876702

Full text available

5
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Material Type:
Article
Add to My Research

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Nature medicine, 2021-11, Vol.27 (11), p.2032-2040 [Peer Reviewed Journal]

2021. The Author(s). ;COPYRIGHT 2021 Nature Publishing Group ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01540-1 ;PMID: 34588689

Full text available

6
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Material Type:
Article
Add to My Research

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

The Lancet (British edition), 2021-05, Vol.397 (10289), p.2043-2046 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01115-6 ;PMID: 33991480

Full text available

7
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Material Type:
Article
Add to My Research

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

New England Journal of Medicine, 2021-06, Vol.384 (23), p.2187-2201 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2101544 ;PMID: 33882225

Digital Resources/Online E-Resources

8
Considerations in boosting COVID-19 vaccine immune responses
Material Type:
Article
Add to My Research

Considerations in boosting COVID-19 vaccine immune responses

The Lancet (British edition), 2021-10, Vol.398 (10308), p.1377-1380 [Peer Reviewed Journal]

2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;2021. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02046-8 ;PMID: 34534516

Full text available

9
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Material Type:
Article
Add to My Research

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

New England Journal of Medicine, 2022-03, Vol.386 (13), p.1207-1220 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2118691 ;PMID: 35172051

Digital Resources/Online E-Resources

10
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Material Type:
Article
Add to My Research

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Science, 2021-02, Vol.371 (6532) [Peer Reviewed Journal]

2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1126/science.abe6959

Digital Resources/Online E-Resources

11
How bad is Omicron? What scientists know so far
Material Type:
Article
Add to My Research

How bad is Omicron? What scientists know so far

Nature (London), 2021-12, Vol.600 (7888), p.197-199 [Peer Reviewed Journal]

Copyright Nature Publishing Group Dec 9, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-021-03614-z ;PMID: 34857948

Full text available

12
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Material Type:
Article
Add to My Research

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

The Lancet infectious diseases, 2021-11, Vol.21 (11), p.1529-1538 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2021 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(21)00289-9 ;PMID: 34174193

Full text available

13
Diagnostics for COVID-19: moving from pandemic response to control
Material Type:
Article
Add to My Research

Diagnostics for COVID-19: moving from pandemic response to control

The Lancet (British edition), 2022-02, Vol.399 (10326), p.757-768 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02346-1 ;PMID: 34942102

Full text available

14
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Material Type:
Article
Add to My Research

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2020-12, Vol.383 (27), p.2603-2615 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;COPYRIGHT 2020 Massachusetts Medical Society ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034577 ;PMID: 33301246

Digital Resources/Online E-Resources

15
A global survey of potential acceptance of a COVID-19 vaccine
Material Type:
Article
Add to My Research

A global survey of potential acceptance of a COVID-19 vaccine

Nature medicine, 2021-02, Vol.27 (2), p.225-228 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2020. corrected publication 2021. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2020, corrected publication 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-020-1124-9 ;PMID: 33082575

Full text available

16
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Material Type:
Article
Add to My Research

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Nature communications, 2021-01, Vol.12 (1), p.372-372, Article 372 [Peer Reviewed Journal]

The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-20653-8 ;PMID: 33446655

Full text available

17
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy
Material Type:
Article
Add to My Research

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy

Nature medicine, 2021-06, Vol.27 (6), p.993-998 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01334-5 ;PMID: 33864052

Full text available

18
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Material Type:
Article
Add to My Research

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

New England Journal of Medicine, 2021-05, Vol.384 (19), p.1824-1835 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034201 ;PMID: 33440088

Digital Resources/Online E-Resources

19
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Material Type:
Article
Add to My Research

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

New England Journal of Medicine, 2021-09, Vol.385 (13), p.1172-1183 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2107659 ;PMID: 34192426

Digital Resources/Online E-Resources

20
Multiple early factors anticipate post-acute COVID-19 sequelae
Material Type:
Article
Add to My Research

Multiple early factors anticipate post-acute COVID-19 sequelae

Cell, 2022-03, Vol.185 (5), p.881-895.e20 [Peer Reviewed Journal]

2022 The Author(s) ;Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. ;2022 The Author(s) 2022 ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2022.01.014 ;PMID: 35216672

Full text available

Results 1 - 20 of 16,484  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (15,545)

Refine My Results

Creation Date 

From To
  1. Before 2018  (1)
  2. 2018 To 2018  (1)
  3. 2019 To 2019  (1)
  4. 2020 To 2021  (12,596)
  5. After 2021  (3,886)
  6. More options open sub menu

Language 

  1. English  (16,152)
  2. Portuguese  (49)
  3. Norwegian  (28)
  4. German  (14)
  5. Spanish  (8)
  6. French  (7)
  7. Polish  (5)
  8. Italian  (4)
  9. Dutch  (4)
  10. Turkish  (3)
  11. Chinese  (3)
  12. Indonesian  (2)
  13. Korean  (2)
  14. Russian  (1)
  15. Croatian  (1)
  16. More options open sub menu

Searching Remote Databases, Please Wait